Fundraising Fox
/Companies
Sign in

Convergent Therapeutics

Cambridge, US · Founded 2021 · 41 employees on LinkedIn · 3 known investors

Find your way into Convergent Therapeutics

Sign up to see every warm intro you have to Convergent Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Convergent Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Convergent Therapeutics develops radioantibody-based (PSMA-targeted) therapies for cancers, including metastatic castration-resistant prostate cancer (mCRPC). The clinical-stage biotech is advancing radiopharmaceutical treatments backed by preclinical and clinical data.

BiotechHealthtech

Founders & leadership

Convergent Therapeutics was founded in 2021 by Philip Kantoff and Neil Bander.

PKPhilip Kantoff
Philip KantoffChief Executive Officer, Co-Founder
NBNeil Bander
Neil BanderSenior Scientific Advisor, Co-Founder
ABAlexander Brown
Alexander BrownCOOAlexander Brown is an executive officer at Convergent Therapeutics with more than two decades of experience in drug development and commercialization, with focus areas including immuno-oncology, oncology, and infectious disease.
ADAndrew Davis
Andrew DavisChief Business and Strategy OfficerAndrew Davis led corporate strategy and transactions across multiple therapeutic areas including dermatology, ophthalmology, oncology, and generics at undisclosed pharmaceutical and healthcare companies. He now serves as Chief Business and Strategy Officer at Convergentrx, a clinical-stage biotech developing radioantibody-based therapies for cancer.
ELElizabeth L. Montgomery
Elizabeth L. MontgomeryChief People OfficerElizabeth Montgomery has over 20 years of experience in people and organizational leadership, including roles building talent functions at ClearView Healthcare Partners and overseeing organizational restructuring at Black Diamond Therapeutics. She holds an MBA and multiple HR certifications.
EMEric M. Sullivan
Eric M. SullivanChief Financial Officer

Board

JSJake Simson
Jake SimsonBoard directorPartner at RA Capital
TZTal Zaks
Tal ZaksNon Executive DirectorPartner at OrbiMed
JT
Jim TrenkleBoard director

Investors · 3

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · board seat on SEC Form D · funding news · press coverage · the VCSheet dataset · Not right? Tell us

InvusreportedNew York

How we know: press coverage · Not right? Tell us

RA CapitalreportedBostonvia Jake Simson · board

How we know: board seat on SEC Form D · funding news · press coverage · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$51.4M disclosed across 2 rounds · 2023–2024

▶$22.2MraisedAug 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SullivanExecutive Officer
  • Jake SimsonDirector
  • Tal ZaksDirector
  • Jim TrenkleDirector
  • Philip KantoffExecutive Officer, Director
  • Alexander BrownExecutive Officer
  • Neil BanderExecutive Officer, Director
Offering amount
$40M
Amount sold
$22.2M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$29.2MraisedMay 2023 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Neil BanderDirector
  • Jake SimsonDirector
  • Philip KantoffExecutive Officer, Director
  • Alexander BrownExecutive Officer
  • Tal ZaksDirector
Offering amount
$99.2M
Amount sold
$29.2M
First sale
Apr 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Convergent Therapeutics do?
Convergent Therapeutics develops radioantibody-based (PSMA-targeted) therapies for cancers, including metastatic castration-resistant prostate cancer (mCRPC). The clinical-stage biotech is advancing radiopharmaceutical treatments backed by preclinical and clinical data.
Who founded Convergent Therapeutics?
Convergent Therapeutics was founded by Philip Kantoff, Neil Bander in 2021.
Who are Convergent Therapeutics's investors?
Convergent Therapeutics's investors include OrbiMed, Invus, RA Capital.
How much funding has Convergent Therapeutics raised?
Convergent Therapeutics has disclosed $51.4M raised across 2 rounds.
Where is Convergent Therapeutics headquartered?
Convergent Therapeutics is headquartered in Cambridge, US.